A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

Part of paid clinical trials in Oakland, California.

Sponsor
Sutter Health
Study ID
NCT06706752
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Shengbai Oral Formula — DIETARY_SUPPLEMENT
    Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.
  • Inactive Placebo — OTHER
    Inactive placebo will be taken by mouth three times per day for 14 days.

Study Details

The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.

Key Dates

Start date
Jan 24, 2025
Status verified
May 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Treatment Group
  • Placebo Comparator: Placebo Group

Primary Outcome Measure

Brief Fatigue Inventory [ Time Frame: 14 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Sutter HealthOaklandCalifornia94609
Janet Han, BSN, RN
[email protected]
510-204-4405
Amy Matecki, MD, FACP, L.Ac (PRINCIPAL_INVESTIGATOR)

Find similar trials in Oakland, CA

By research site
Sutter Health· Oakland, CA

Related Studies